Sarepta Therapeutics (SRPT) Stock: Investors Brace for Pivotal Monday Data Release

TLDR

• Sarepta Therapeutics announces January 26 release of 3-year EMBARK study data for Elevidys gene therapy at 8:30 am ET
• Stock dropped 3% to $21.13 Friday but surged 5% after hours to $22.20 on the announcement
• FDA restricted Elevidys to ambulatory patients only after acute liver failure deaths in non-ambulatory patients
• Company reported $898.7 million in Elevidys revenue for 2025, part of $1.86 billion total product revenue
• Monday’s data crucial for proving long-term effectiveness and addressing safety concerns after recent label restrictions

Sarepta Therapeutics shares rallied in extended trading Friday after announcing a Monday morning data presentation. The stock closed regular hours down 3% at $21.13 but jumped to approximately $22.20 after hours, marking a 5% gain.

Sarepta Therapeutics, Inc., SRPT

The biotech company will unveil 3-year topline functional results from its EMBARK Phase 3 study on January 26 at 8:30 am Eastern Time. The presentation comes one hour before markets open, setting up potential volatility at the opening bell.

EMBARK is a randomized, placebo-controlled trial evaluating Elevidys in ambulatory Duchenne muscular dystrophy patients aged four to seven. The study structure provides stronger evidence than open-label trials but demands clearer proof of effectiveness.

Recent Label Changes Drive Urgency

The timing of Monday’s release carries extra weight following recent regulatory action. FDA imposed its strongest safety warning on Elevidys and limited use to patients who can walk after deaths from acute liver failure occurred in non-ambulatory patients.

Two deaths under investigation prompted Sarepta to halt shipments to non-ambulatory patients. The company is collaborating with regulators on updated monitoring requirements and label modifications.

Parent Project Muscular Dystrophy raised concerns, stating “serious questions remain about the safety and long-term outcomes of these therapies.” These worries put pressure on Monday’s 3-year data to demonstrate sustained benefits without new safety signals.

Gene therapies face their toughest test at the three-year mark. Investors need proof that initial improvements persist and that delayed safety issues don’t emerge after the treatment honeymoon period ends.

Revenue Picture Remains Mixed

Sarepta disclosed preliminary 2025 net product revenue of $1.86 billion earlier this month. Elevidys accounted for $898.7 million despite a challenging fourth quarter that brought in just $110.4 million.

CEO Doug Ingram blamed a severe flu season for forcing patient infusion delays. Many procedures scheduled for December shifted into 2026, creating a revenue timing issue rather than a demand problem.

The stock has climbed 63.59% over six months despite ongoing challenges. However, recent safety concerns have created uncertainty around growth trajectory.

Pfizer’s failure with its Duchenne gene therapy candidate in 2024 highlighted the difficulty of translating dystrophin production into measurable functional improvements. That setback adds pressure on Sarepta to show clear benefits.

Traders will parse Monday’s data for durability signals and any mention of adverse events. Gene therapies administered once leave no room for course corrections, making safety data especially critical.

The webcast will be available on Sarepta’s investor relations page with a replay archived for one year. Phone participants need advance registration for dial-in access.

Full fourth-quarter and 2025 results are scheduled for late February, providing additional clarity on commercial momentum for Elevidys following Monday’s clinical update.